ABEONA THERAPEUTICS INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ABEONA THERAPEUTICS INC. (ABEO) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$6.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $978.00K, a 73.42% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$7.32M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $4.24M, a 148.27% increase year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.00M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $6.54M, a 333.97% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.51M, a 26.16% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.04M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$4.11M, a 597.94% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $978.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$6.34M 10-Q · filed 2026-08-13 | -$2.10M derived: sum of 3 quarters · filed 2026-08-13 | -$1.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$7.32M 10-Q · filed 2026-05-13 | -$3.08M derived: sum of 2 quarters · filed 2026-05-13 | -$2.08M derived: sum of 3 quarters · filed 2026-05-13 | $1.60M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.24M derived: sum of 2 quarters · filed 2026-03-17 | $8.92M derived: sum of 3 quarters · filed 2026-08-13 | $6.54M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.68M derived: sum of 2 quarters · filed 2026-08-13 | $2.30M 10-Q · filed 2025-11-12 | $4.01M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.30M 10-Q · filed 2026-08-13 | $3.01M derived: sum of 3 quarters · filed 2026-08-13 | $2.93M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$2.38M 10-Q · filed 2026-05-13 | -$671.00K derived: sum of 2 quarters · filed 2026-05-13 | -$750.00K derived: sum of 3 quarters · filed 2026-05-13 | $819.00K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.63M derived: sum of 2 quarters · filed 2026-03-17 | $3.20M derived: sum of 3 quarters · filed 2026-03-17 | $1.51M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.49M derived: sum of 2 quarters · filed 2025-11-12 | -$200.00K 10-Q · filed 2025-11-12 | $1.08M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$121.00K 10-Q · filed 2025-08-14 | $1.16M derived: sum of 3 quarters · filed 2025-08-14 | $84.00K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$1.69M 10-Q · filed 2025-05-15 | -$411.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.49M derived: sum of 3 quarters · filed 2025-05-15 | $727.00K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $205.00K derived: sum of 2 quarters · filed 2025-03-20 | $2.42M derived: sum of 3 quarters · filed 2025-03-20 | $2.04M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.14M derived: sum of 2 quarters · filed 2024-11-14 | $762.00K 10-Q · filed 2024-11-14 | -$142.00K 10-Q · filed 2023-11-13 | $1.78M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.84M 10-Q · filed 2024-08-12 | $1.21M 10-Q · filed 2023-08-08 | $2.85M derived: sum of 3 quarters · filed 2024-08-12 | $1.41M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$376.00K 10-Q · filed 2024-05-15 | -$684.00K 10-Q · filed 2023-05-11 | $641.00K derived: sum of 2 quarters · filed 2024-05-15 | -$800.00K derived: sum of 3 quarters · filed 2024-05-15 | -$98.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$424.00K derived: sum of 2 quarters · filed 2024-03-18 | $278.00K derived: sum of 3 quarters · filed 2024-03-18 | -$4.11M 10-K · filed 2024-03-18 | -$5.49M 10-K · filed 2023-03-29 | |||
| 2022-09-30 | -$1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$739.00K derived: sum of 2 quarters · filed 2023-11-13 | -$5.13M 10-Q · filed 2023-11-13 | $159.00K derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $702.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.68M 10-Q · filed 2023-08-08 | $1.60M derived: sum of 3 quarters · filed 2023-08-08 | $2.12M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | -$4.39M 10-Q · filed 2023-05-11 | $898.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.42M derived: sum of 3 quarters · filed 2023-05-11 | -$537.00K derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $5.80M derived: sum of 2 quarters · filed 2023-03-29 | $3.85M derived: sum of 3 quarters · filed 2023-03-29 | $825.00K 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $518.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.44M derived: sum of 2 quarters · filed 2022-11-14 | -$4.46M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$4.98M 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | -$3.02M 10-Q · filed 2022-05-13 | |||||||
| 2015-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$443.00K derived: sum of 2 quarters · filed 2016-03-30 | $84.00K derived: sum of 3 quarters · filed 2016-03-30 | -$1.17M 10-K · filed 2016-03-30 | ||||
| 2015-09-30 | -$350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $177.00K derived: sum of 2 quarters · filed 2015-11-16 | -$1.08M 10-Q · filed 2015-11-16 | -$1.81M derived: sum of 4 quarters · filed 2016-03-30 | ||||
| 2015-06-30 | $527.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$731.00K 10-Q · filed 2015-08-14 | -$1.47M derived: sum of 3 quarters · filed 2016-03-30 | -$1.18M derived: sum of 4 quarters · filed 2016-03-30 | ||||
| 2015-03-31 | -$1.26M 10-Q · filed 2015-05-14 | -$1.99M derived: sum of 2 quarters · filed 2016-03-30 | -$1.70M derived: sum of 3 quarters · filed 2016-03-30 | -$1.44M derived: sum of 4 quarters · filed 2016-03-30 | ||||
| 2014-12-31 | -$734.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$444.00K derived: sum of 2 quarters · filed 2016-03-30 | -$179.00K derived: sum of 3 quarters · filed 2016-03-30 | $33.00K 10-K · filed 2016-03-30 | ||||
| 2014-09-30 | $290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $555.00K derived: sum of 2 quarters · filed 2015-11-16 | $767.00K 10-Q · filed 2015-11-16 | $924.00K derived: sum of 4 quarters · filed 2015-11-16 | ||||
| 2014-06-30 | $265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $477.00K 10-Q · filed 2015-08-14 | $634.00K derived: sum of 3 quarters · filed 2015-08-14 | $35.00K derived: sum of 4 quarters · filed 2015-08-14 | ||||
| 2014-03-31 | $212.00K 10-Q · filed 2015-05-14 | $369.00K derived: sum of 2 quarters · filed 2015-05-14 | -$230.00K derived: sum of 3 quarters · filed 2015-05-14 | -$1.31M derived: sum of 4 quarters · filed 2015-05-14 | ||||
| 2013-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | -$442.00K derived: sum of 2 quarters · filed 2015-03-31 | -$1.52M derived: sum of 3 quarters · filed 2015-03-31 | -$1.18M 10-K · filed 2015-03-31 | ||||
| 2013-09-30 | -$599.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | -$1.68M derived: sum of 2 quarters · filed 2014-11-14 | -$1.33M 10-Q · filed 2014-11-14 | -$1.40M derived: sum of 4 quarters · filed 2014-11-14 | ||||
| 2013-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$734.00K 10-Q · filed 2014-08-14 | -$801.00K derived: sum of 3 quarters · filed 2014-08-14 | -$864.00K derived: sum of 4 quarters · filed 2014-08-14 | ||||
| 2013-03-31 | $346.00K 10-Q · filed 2014-05-12 | $279.00K derived: sum of 2 quarters · filed 2014-05-12 | $216.00K derived: sum of 3 quarters · filed 2014-05-12 | $748.00K derived: sum of 4 quarters · filed 2014-05-12 | ||||
| 2012-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | -$130.00K derived: sum of 2 quarters · filed 2014-03-26 | $402.00K derived: sum of 3 quarters · filed 2014-03-26 | $567.00K 10-K · filed 2014-03-26 | ||||
| 2012-09-30 | -$63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $469.00K derived: sum of 2 quarters · filed 2013-11-14 | $634.00K 10-Q · filed 2013-11-14 | $760.00K derived: sum of 4 quarters · filed 2013-11-14 | ||||
| 2012-06-30 | $532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $697.00K 10-Q · filed 2013-08-14 | $823.00K derived: sum of 3 quarters · filed 2013-08-14 | $787.00K derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2012-03-31 | $165.00K 10-Q · filed 2013-05-15 | $291.00K derived: sum of 2 quarters · filed 2013-05-15 | $255.00K derived: sum of 3 quarters · filed 2013-05-15 | $310.00K derived: sum of 4 quarters · filed 2013-05-15 | ||||
| 2011-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-20 | $90.00K derived: sum of 2 quarters · filed 2013-03-20 | $145.00K derived: sum of 3 quarters · filed 2013-03-20 | $53.00K 10-K · filed 2013-03-20 | ||||
| 2011-09-30 | -$36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $19.00K derived: sum of 2 quarters · filed 2012-11-14 | -$73.00K 10-Q · filed 2012-11-14 | -$1.35M 10-Q · filed 2011-11-14 | -$472.00K derived: sum of 4 quarters · filed 2012-11-14 | |||
| 2011-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | -$37.00K 10-Q · filed 2012-08-14 | -$436.00K derived: sum of 3 quarters · filed 2012-08-14 | -$41.00K derived: sum of 4 quarters · filed 2012-08-14 | ||||
| 2011-03-31 | -$92.00K 10-Q · filed 2012-05-15 | -$491.00K derived: sum of 2 quarters · filed 2012-05-15 | -$96.00K derived: sum of 3 quarters · filed 2012-05-15 | |||||
| 2010-12-31 | -$399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23 | -$4.00K derived: sum of 2 quarters · filed 2012-03-23 | -$601.00K 10-K · filed 2012-03-23 | |||||
| 2010-09-30 | $395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | -$202.00K 10-Q · filed 2011-11-14 | ||||||
| 2010-06-30 | -$597.00K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |